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Abstract
Warm ischemia-reperfusion injury remains a crucial issue in transplantation following the cardiac death of donors.
Previously, we showed that surfactant inhalation during warm ischemia mitigated ischemia-reperfusion injury. This study
investigated the mechanisms of surfactant inhalation protection of the warm ischemic lung after reoxygenation with
ventilation alone. In an isolated rat lung ventilation model, cardiac arrest was induced in the CTRL (control) and SURF
(surfactant treatment) groups by ventricular fibrillation. Ventilation was restarted 110 min later; the lungs were flushed, and
a heart and lung block was procured. In the SURF group, a natural bovine surfactant (SurfactenH) was inhaled for 3 min at
the end of warm ischemia. In the Sham (no ischemia) group, lungs were flushed, procured, and ventilated in the same way.
Afterwards, the lungs were ventilated with room air without reperfusion for 60 min. Surfactant inhalation significantly
improved dynamic compliance and airway resistance. Moreover, surfactant inhalation significantly decreased inducible nitric
oxide synthase and caspase-3 transcript levels, and increased those of Bcl-2 and surfactant protein-C. Immunohistochem-
ically, lungs in the SURF group showed weaker staining for 8-hydroxy-29-deoxyguanosine, inducible nitric oxide synthase,
and apoptosis, and stronger staining for Bcl-2 and surfactant protein-C. Our results indicate that surfactant inhalation in the
last phase of warm ischemia mitigated the injury resulting from reoxygenation after warm ischemia. The reduction in
oxidative damage and the inhibition of apoptosis might contribute to the protection of the warm ischemic lungs.
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Introduction
To deal with the shortage of donor organs in lung transplan-
tation, donation after cardiac death (DCD) has been introduced
worldwide as a potential strategy to increase the donor pool. Since
lung transplantation from uncontrolled DCD donors was first
successfully performed in 2000 [1], several programs have
subsequently reported acceptable outcomes comparable to dona-
tion after brain death [2,3]. However, warm ischemia inevitably
occurs in DCD donors after cardiac arrest and may cause
ischemia-reperfusion (I-R) injury after transplantation.
The presence of the airway has made it possible to protect graft
lungs by inflation [4,5], ventilation with oxygen [5,6], and drug
administration, even after circulation has stopped in DCD donors.
Moreover, we previously reported the protective effects of
preprocurement ventilation [7] and the inhalation of several drugs
[8–10].
A pulmonary surfactant is primarily composed of phospholipids
and surfactant proteins, and functions to reduce the surface
tension in the alveoli through forming a monolayer at the air-lipid
interface. This mechanism prevents alveolar collapse [11,12] and
protects the lung. Surfactants have been administered in clinical
settings to patients with severe primary graft dysfunction after
transplantation [13,14] and for donor lungs [15]. However,
surfactant function has been reported to deteriorate with
increasing warm ischemic time intervals [12]. Recently, we
reported that surfactant inhalation in the last phase of warm
ischemia attenuated I-R injury in an ex vivo rat lung perfusion
model [16] and in a canine lung transplantation model [17]. We
found that prerecovery surfactant inhalation improved graft lung
function, maintained adenine nucleotide levels, and prevented
cytokine production, resulting in attenuation of warm I-R injury
[16]. Van Putte et al. also reported that exogenous surfactant
resulted in anti-inflammation, which was accompanied by
decreased apoptosis [18]. Hence, surfactant inhalation could serve
as a potential method to reduce the severity of I-R injury.
However, both reports demonstrated that various factors could
have potentially induced I-R injury.
I-R commonly corresponds to anoxia-reoxygenation in organ
transplantation [19]. However, the I-R injury in lungs is
physiologically different from that in other organs with systemic
circulation. First, the lung cells are able to maintain aerobic
metabolism by using the oxygen in the alveoli even after the
cessation of circulation [4,5]. Second, the lungs can undergo
reoxygenation without reperfusion, if only with ventilation.
Consequently, the lung affords a unique opportunity to separate
the effects of reperfusion and reoxygenation on tissue function.
We hypothesized that surfactant inhalation could mitigate
hypoxia-reoxygenation injury. Here, the study aim was to clarify
the effect of surfactant inhalation against injury resulting from
reoxygenation with ventilation alone after warm ischemia to
explore the mechanism of surfactant against I-R injury.
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Materials and Methods
Ethics Statement
Specific pathogen-free inbred male Lewis rats weighing 285–
305 g (Japan SLC, Hamamatsu, Japan) were used in these studies.
All animals received humane care in compliance with the
Principles of Laboratory Animal Care formulated by the National
Society for Medical Research, and the ‘‘Guide for the Care and
Use of Laboratory Animals,’’ prepared by the Institute of
Laboratory Animal Resources and published by the National
Institute of Health (NIH Publication 85–23, revised 1996). The
study protocol was approved by the Ethical Committee of the
Graduate School of Medicine at Kyoto University, Japan.
Surfactant and Aerosol Delivery
A 30-mg/ml surfactant solution was obtained by dissolving
beractant (SurfactenH, Mitsubishi Tanabe Pharma Corporation,
Osaka, Japan) with normal saline (0.9%) and then aerosolized by a
nebulizer (AGAL1000, Aerogen, Ireland), which was put into the
inspiratory loop of the ventilator. In this system, the diameters of
,90% and ,60% of the aerosolized particles were maintained
below 10 mm and 3.0 mm, respectively. In each experiment for the
SURF (surfactant treatment) group, 0.4 mL of fluid was loaded
and aerosolized for 3 min.
Study Design
Rats were anesthetized with an intraperitoneal injection of
sodium pentobarbital (50 mg/kg), intubated after tracheotomy,
and ventilated with ambient air at positive pressure. Isolated rat
lung ventilation was performed using a Hugo-Sachs Elektronik-
Harvard Apparatus (Model 829; March-Hugstetten, Germany), as
previously reported [16]. The animals were randomly allocated to
three groups: Sham, CTRL, and SURF. In the CTRL and SURF
groups, after a medial abdominal incision and a median
sternotomy were performed, cardiac arrest was induced by
ventricular fibrillation. The ventricular fibrillation was induced
by a fibrillator attached directly to the right atrium and apex of the
heart and continued for 7 min at 2.00 V. Cardiac arrest was
defined as the complete immobility of the ventricles. After
confirmation of cardiac arrest, the ventilator was stopped, and
the lungs were completely collapsed. The chest was closed with
skin staplers and then placed in a Styrofoam box. After 110 min of
cardiac arrest period, the lungs were completely re-expanded
below the pressure of 30 cmH2O, and positive pressure ventilation
was restarted. The pulmonary artery was cannulated directly, and
the lungs were flushed with 20 ml of 37uC low-potassium dextran
solution (PerfadexH, Vitrolife, Uppsala, Sweden) at a pressure of
20 cmH2O, and drained through an incision at the apex of the left
ventricle. The cannula of the pulmonary artery was pulled out,
and the heart and lung block was subsequently procured and
placed in the artificial thorax. The test lung was then ventilated
with room air at negative pressure under the following conditions:
Figure 1. Physiological lung functions during ventilation. (A) Airway resistance. (B) Dynamic compliance. **p,0.01 or ***p,0.001 between the
Sham (open circles) and CTRL groups (boxes). {p,0.05 or {{p,0.01 or {{{p,0.001 between the CTRL and SURF groups (solid circles). 1p,0.05
between the Sham and SURF groups. Data are expressed as mean values 6 SD (BL =baseline).
doi:10.1371/journal.pone.0072574.g001
Figure 2. Adenine nucleotide levels. ATP, adenosine triphosphate;
ADP, adenosine diphosphate; AMP, adenosine monophosphate; dw, dry
weight. Data are shown as mean 6 SD.
doi:10.1371/journal.pone.0072574.g002
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respiratory rate = 60 cycles/min; peak inspiratory and expiratory
chamber pressures = –8 and –4 cmH2O, respectively; ratio of
inspiratory duration= 50%. The artificial thorax and the airway
were water-jacketed to maintain the temperature at 37uC
throughout the experiment. In the SURF group (n= 5), the
surfactant was inhaled for 3 min just after the beginning of
negative pressure ventilation. In the CTRL group (n = 5), no
inhalation was performed. In the Sham group (n= 5), the lungs
were flushed with PerfadexH, and thereafter procured and
ventilated in the same way. At the end of the inhalation, the
time was set as baseline, and the evaluation was commenced with
airway resistance (cmH2O/ml) and dynamic compliance (ml/
cmH2O) continuously monitored for 60 min.
Adenine Nucleotide Levels
Pieces of the right middle and lower lobes of each lung were
collected immediately after flushing the pulmonary vascular bed
Figure 3. mRNA expression of cytokines after reperfusion. (A) iNOS mRNA levels. (B) Caspase-3 mRNA levels. (C) Bcl-2 mRNA levels. (D) Bax
mRNA levels. (E) SP-C mRNA levels. All values are expressed as the mean 6 SD.
doi:10.1371/journal.pone.0072574.g003
Figure 4. Caspase Activation Assay. All values are expressed as the
mean 6 SD.
doi:10.1371/journal.pone.0072574.g004
Figure 5. Immunohistochemical staining and the assessment
for oxidative damage (original magnification 4006). (A) Sham
group. (B) CTRL group. (C) SURF group. In the 8-OHdG staining, the ratio
of 8-OHdG-positive cells was significantly lower in the Sham and SURF
groups than that in the CTRL group (D). All values are expressed as the
mean 6 SD.
doi:10.1371/journal.pone.0072574.g005
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with warm saline (37uC) at the end of the evaluation. The
adenosine triphosphate (ATP), adenosine diphosphate (ADP), and
adenosine monophosphate (AMP) levels were measured by high-
performance liquid chromatography, as previously described [16].
Messenger RNA (mRNA) Expression
Left lung specimens were collected after the 60 min of
evaluation. Five genes were examined by real-time reverse
transcription-polymerase chain reaction as previously described
[16]. Quantities of the genes of interest were calculated from
corresponding standard curves and are presented here relative to
the amount of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Caspase Activation Assay
Caspase-3/7 activities were measured using Caspase-GloH 3/7
Assay kit (Promega, Madison, WI, USA) according to manufac-
turer’s instructions. Briefly, the supernatant of each specimen were
seeded in 96-well plates and Caspase-Glo 3/7 reagent was added
to each well in a 1:1 ratio and incubated for 60 minutes before
measuring luminescence as relative light units (RLUs) using a
GloMaxH-Multi Detection System (Promega, Madison, WI, USA).
Caspase activity was normalized to the protein concentration using
the Bradford protein assay. Caspase activity was represented as
ratio to that in the Sham group.
Pathological Evaluation
After 60 min of evaluation, 10% formalin was instilled
intratracheally into the right upper and mediastinal lobes, which
were subsequently embedded in paraffin and investigated by
hematoxylin-eosin (H–E) staining.
Immunohistochemical Analysis
The avidin-biotin complex method was used for immunohisto-
chemical staining, as previously reported [20,21]. The primary
antibodies for incubation were as follows; 8-hydroxy-29-deoxy-
guanosine (8-OHdG): Anti-8-OHdG monoclonal antibody N45.1
(JaICA, Shizuoka, Japan), inducible nitric oxide synthase (iNOS):
Rabbit Anti-Human iNOS Polyclonal Antibody (Spring Biosci-
ence, Pleasanton, USA), Bcl-2: Bcl-2 (C-2): sc-7382 (Santa Cruz
Biotechnology, Santa Cruz, USA), SP-C: SP-C (FL 197): sc-13979
(Santa Cruz Biotechnology). Quantification of the immunohisto-
logical data was performed blindly by 2 independent investigators
(J.S. and D.N.) as a mean of the ratio of 8-OHdG-, iNOS-, and
Bcl-2-positive cells to total cells in 10 randomly chosen high-power
fields (HPF) per section at a magnification of 4006. Because SP-C
was produced by only alveolar type II cells, SP-C staining was
assessed as a mean number of the SP-C-positive cells in the same
manner.
TUNEL Assay
Apoptotic cells were stained by the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) technique
using an apoptosis in situ detection kit (Wako Jyunyaku, Osaka,
Japan), as previously reported [7]. Apoptosis was expressed as a
mean of the ratio of TUNEL-positive cells to total cells in the same
manner as the immunohistochemical analysis.
Statistical Analysis
All statistical analyses were performed using StatView 5.0
software (Abacus Concepts, Berkeley, California). All values are
presented as the mean 6 the standard deviation. Data were
evaluated using one-way analysis of variance (ANOVA), Scheffe’s
post-hoc multiple comparison test to explore differences between
the groups. A p value ,0.05 was considered statistically
significant.
Results
The body weights were similar between the Sham, CTRL, and
SURF groups (29764.0 g, 29666.2 g, and 29565.0 g, respec-
tively). All lungs were ventilated and evaluated successfully in
60 min.
Physiological Parameters
In the CTRL group, airway resistance increased and dynamic
compliance decreased during the latter half of the evaluation
period, and were significantly higher and lower than those in the
Sham group (p,0.001 and p,0.01 at 60 minutes after evaluation
period). However, in the SURF group, the airway resistance and
dynamic compliance were maintained at almost the same levels as
those at the initiation of the evaluation, and were significantly
lower and higher, respectively, than those in the CTRL group
(p,0.001 and p,0.05 at 60 minutes, respectively; Figure 1A and
B).
Adenine Nucleotide Levels
After 60 min of ventilation, although we did not have statistical
significance, the ATP levels in the SURF group tended to be
higher than that in the CTRL group. The differences in ADP and
AMP levels between the groups did not reach significance
(Figure 2).
Evaluation of mRNA Expression
After 60 min of ventilation, the mRNA expression of iNOS and
caspase-3 was significantly lower in the Sham and SURF groups
than that in the CTRL group (Figure 3A and B). Meanwhile, the
B-cell lymphoma-2 gene product (Bcl-2) mRNA levels in the
SURF group were significantly higher than those in the CTRL
Figure 6. Immunohistochemical staining for iNOS (original
magnification 400 6). (A) Sham group. (B) CTRL group. (C) SURF
group. Arrows indicate iNOS positive cells. The ratio of iNOS-positive
cells to total cells was significantly lower in the SURF group than in the
CTRL group (D). All values are expressed as the mean 6 SD.
doi:10.1371/journal.pone.0072574.g006
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Figure 7. TUNEL assay (original magnification 4006). (A) Sham group. (B) CTRL group. (C) SURF group. The ratio of apoptotic cells to total cells
in the Sham and SURF groups was significantly lower than that in the CTRL group (D). All values are expressed as the mean 6 SD.
doi:10.1371/journal.pone.0072574.g007
Figure 8. Immunohistochemical staining for Bcl-2 (original
magnification 400 6). (A) Sham group. (B) CTRL group. (C) SURF
group. Arrows indicate Bcl-2 positive cells. The ratio of Bcl-2-positive
cells was significantly higher in the SURF group than that in the CTRL
group (D). All values are expressed as the mean 6 SD.
doi:10.1371/journal.pone.0072574.g008
Figure 9. Immunohistochemical staining for SP-C (original
magnification 4006). (A) Sham group. (B) CTRL group. (C) SURF
group. The amount of SP-C-positive cells in the CTRL and SURF groups
was significantly lower than that in the Sham group, however, that in
the SURF group was significantly higher than that in the CTRL group
(D). All values are expressed as the mean 6 SD.
doi:10.1371/journal.pone.0072574.g009
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group (Figure 3C). Bcl-2 associated X-protein (Bax) mRNA levels
did not differ between the study groups (Figure 3D). The SP-C
mRNA levels in the SURF group were significantly lower than
that in the Sham group and higher than that in the CTRL group
(Figure 3E).
Caspase Activation Assay
After 60 min of ventilation, there was a threefold increase in
Caspase-3/7 activity in the CTRL group compared to that in the
Sham group. Caspase-3/7 activity in the SURF group was more
than twice as much as that in the Sham group, but was
significantly lower than that in the CTRL group (Figure 4).
Pathological Examination
The lungs of 3 groups had a relatively normal structure, with no
evident differences between the groups.
Oxidative Damage After Reoxygenation
Oxidative damage was evaluated immunohistochemically by
examining 8-OHdG expression [22]. The CTRL group
(Figure 5B) showed more intense nuclear staining for 8-OHdG
than the Sham and SURF groups (Figure 5A and C). Moreover,
the ratio of 8-OHdG-positive cells was significantly lower in the
Sham and SURF groups than that in the CTRL group (Figure 5D).
Immunohistochemical Staining for iNOS
In all groups, the staining for iNOS was weak and unclear
(Figure 6A, B, and C). However, the ratio of iNOS-positive cells
was significantly lower in the SURF group than that in the CTRL
group (Figure 6D).
TUNEL Assay
The ratio of apoptotic cells to total cells in the Sham and SURF
groups was significantly lower than that in the CTRL group
(Figure 7A, B, C, and D).
Immunohistochemical Staining for Bcl-2
The ratio of Bcl-2-positive cells was significantly higher in the
SURF group than that in the CTRL group (Figure 8A, B, C, and
D).
Immunohistochemical Staining for SP-C
The staining of type II cells was sporadic in the CTRL group
(Figure 9B), but homogeneous and clear in the Sham and SURF
groups (Figure 9A and C). The amount of SP-C-positive cells in
the CTRL and SURF groups was significantly lower than that in
the Sham group, however, that in the SURF group was
significantly higher than that in the CTRL group (Figure 9D).
Discussion
In this study, we investigated whether surfactant inhalation in
the last phase of warm ischemia could mitigate injury resulting
from reoxygenation in an isolated rat lung ventilation model. We
found that a reduction in oxidative stress and inhibition of
apoptosis may contribute to maintaining the viability of alveolar
type II cells, leading to the protection of warm ischemic lungs.
Initially, we explored the anti-oxidative effects of surfactant
inhalation after resuming only the ventilation. Nitric oxide (NO) is
a vasodilator and bronchodilator molecule with a critical role in
numerous physiologic and inflammatory processes in the lung
[23], and iNOS is present in various cell types and increased by a
variety of inflammatory stimuli [24]. Large amounts of NO
generated by iNOS can be toxic and pro-inflammatory [25], and
may promote peroxynitrite radical formation [26]. In the current
study, surfactant inhalation significantly decreased iNOS produc-
tion, resulting in the reduction of oxidative damage. Van Putte
et al. reported that surfactant treatment decreased iNOS expres-
sion at 30 min of reperfusion in a rat lung ischemia-reperfusion
model, consistent with our results [18]. Moreover, Miles et al.
showed that lung surfactant inhibited lipopolysaccharide (LPS)-
induced NO production by alveolar macrophages, that the effect is
due to a reduction in iNOS protein levels, and that SP-B was the
surfactant component responsible for the reduction [27]. Based on
these findings, we believe that surfactant prevents iNOS produc-
tion, leading to a decrease in the down-regulation of surfactant by
iNOS. Consistent with this theory, in the current study, the SURF
group maintained predominance in the dynamic compliance.
Increased lung apoptosis has been shown to be one of the
mechanisms through which iNOS and inducible NO cause I-R
lung injury [28]. When NO is supplied in excess, as in hypoxia-
reoxygenation situations, the part of it released from NOS can
rapidly react with superoxidase to form peroxynitrite, an oxidizing
agent [29]. This species can cause lipid peroxidation, apoptosis,
alterations in DNA, and protein nitration and oxidation, all of
which can lead to profound cellular disturbances [30]. Therefore,
based on our data demonstrating that surfactant reduced oxidative
damage, we hypothesized that surfactant may induce apoptotic
proteins. We used assays for activated caspase-3 activity, a
terminal effector of apoptosis [31], and found that surfactant
inhalation significantly reduced caspase-3 mRNA levels and
caspase-3/7 activity, consistent with van Putte et al. [18]. This
result could explain the reduced apoptotic cells in the SURF
group. Bcl-2 is a well-studied antiapoptotic protein, and is thought
to inhibit apoptosis by stabilizing the outer mitochondrial
membrane, preventing release of cytochrome c into the cytosol
and thereby blocking caspase activation [32]. In the current study,
mRNA and protein expressions of Bcl-2 in the SURF group were
significantly higher than those in the CTRL group. Prior studies
have demonstrated that Bcl-2 overexpression in donor grafts is
cytoprotective [31,33,34]. Further, caspase-3-dependent cleavage
of Bcl-2 promotes further caspase activation as part of a positive
feedback loop for executing the cell [35]. Reduced caspase-3
activity by surfactant inhalation might cut off the feedback loop for
apoptosis.
Mitochondrial membrane permeability is directly controlled by
the Bcl-2 family of proteins primarily through regulating the
formation of apoptotic protein-conducting pores in the outer
mitochondrial membrane [36]. The inhibition of apoptosis could
lead to the maintenance of cell viability. Furthermore, ATP
synthesis, coupled to cellular respiration, occurs in the mitochon-
dria, and irreversible damage at the level of oxidative phosphor-
ylation can lead to cell death by energy deprivation [37]. The
current study showed that surfactant inhalation led not only to the
inhibition of apoptosis but to the maintenance of ATP levels. In
addition, the levels of SP-C, a marker of cell viability of type II
cells, were also maintained more in the SURF group than in the
CTRL group.
Our study had several limitations. First, a small animal ex vivo
model was used as opposed to an actual lung transplantation
model. Second, no cold preservation was applied, which is always
required clinically; and the lungs were ventilated with negative
pressure. Third, the lungs were completely collapsed during warm
ischemia, which is different from clinical settings.
In conclusion, we confirmed that only 3 min of surfactant
inhalation in the last phase of warm ischemia mitigated the injury
resulting from reoxygenation in an isolated rat lung ventilation
Surfactant Inhalation against Warm Ischemic Injury
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model. The reduction in oxidative damage and the inhibition of
apoptosis may contribute to the protection of the warm ischemic
lungs in our study. Hence, surfactant inhalation could be a
convenient and effective method for improving graft function in
lung transplantation from DCD donors.
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